Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials (vol 144, pg 321, 2018)
Por:
Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, Geissler M, Koukakis R, Demonty G and Peeters M
Publicada:
1 abr 2018
Resumen:
The authors would like to include the following changes in the published article.
Filiaciones:
Taieb J:
Department of Hepatogastroenterology and GI Oncology, Georges Pompidou European Hospital and Sorbonne Paris Cité / Université Paris Descartes, 20 rue Leblanc, 75015, Paris, France.
Rivera F:
Hospital Universitario Marqués de Valdecilla, Santander, Spain
Siena S:
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda and Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy
Karthaus M:
Städtisches Klinikum München, Klinikum Neuperlach, Munich, Germany
Valladares-Ayerbes M:
Virgen del Rocio Hospital, Seville, Spain
:
Hospital General Universitario de Elche, Elche, Spain
Geissler M:
Klinikum Esslingen, Esslingen, Germany
Koukakis R:
Biostatistics, Amgen Ltd, Uxbridge, UK
Demonty G:
Medical Development, Amgen (Europe) GmbH, Zug, Switzerland
Peeters M:
Antwerp University Hospital, Antwerp, Belgium
Green Published, Bronze
|